开发艾滋病疫苗的挑战和机遇
1Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-3005, USA. gnabel@nih.gov
Nature
|April 20, 2001
概括
人类免疫缺陷病毒 (HIV) 流行不成比例地影响发展中国家,造成广泛的痛苦. 由于抗病毒药物分发的挑战,开发有效的疫苗对于全球控制至关重要.
科学领域:
- 全球健康 全球健康
- 流行病学 流行病学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 获得性免疫缺陷综合征 (艾滋病) 在全球范围内产生了毁灭性的后果,特别是在发展中国家.
- 疫情导致了大量的人类痛苦,生命损失和社会经济不稳定.
- 全球范围内,人类免疫缺陷病毒 (HIV) 抗病毒药物获取受到成本和后勤挑战的限制.
研究的目的:
- 强调迫切需要替代性艾滋病毒/艾滋病控制战略.
- 强调疫苗开发在应对全球流行病中的关键作用.
- 为了强调生物医学界对疫苗作为可持续解决方案的关注.
主要方法:
- 本摘要没有详细说明具体方法,而是讨论了疫苗研究的一般方法.
- 它暗示着关注生物医学干预的挑战和潜力.
- 背景表明对艾滋病毒/艾滋病管理状况的审查或观点.
主要成果:
- 摘要并没有介绍具体的结果,而是构建了问题的陈述.
- 它确定了当前抗病毒治疗在广泛应用中的局限性.
- 它指出疫苗开发是正在进行的研究和未来希望的关键领域.
结论:
- 疫苗开发是打击全球艾滋病毒/艾滋病流行病的关键优先事项.
- 克服抗病毒药物输送的挑战需要像疫苗这样的创新解决方案.
- 生物医学研究正在积极寻求疫苗,以减轻全球艾滋病毒/艾滋病的影响.
相关概念视频
Retrovirus Life Cycles
42.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
42.8K
Development of Immunocompetence
1.2K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K
Immunodeficiency Diseases
3.4K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
3.4K
Cancer Vaccines
1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Microorganisms in Medicine and Therapeutics
1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Vaccine Production
129
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
129


